Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

1.5K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
1.5K
Analgesia and Pain Management01:25

Analgesia and Pain Management

732
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
732
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

380
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
380
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

328
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
328
Community Based Intervention01:30

Community Based Intervention

87
Community-based interventions in mental health represent a paradigm shift from institution-centered care to treatments embedded within the fabric of local communities. By prioritizing inclusion and leveraging existing societal structures, this approach fosters a supportive environment conducive to addressing mental health challenges while promoting individual dignity and agency.
Foundations of Community Mental Health Programs
Central to the success of community-based interventions is the...
87
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

619
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
619

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Virtual Reality-Based Cognitive Restorative Intervention Using Nature to Improve Attention, Self-Care, and Health-Related Quality of Life in Heart Failure.

The Journal of cardiovascular nursing·2026
Same author

Molecular pathogenesis of <i>Haemophilus ducreyi</i> infection in human volunteers.

Microbiology and molecular biology reviews : MMBR·2025
Same author

Enrichment of mutant calmodulin protein in a murine model of a human calmodulinopathy.

JCI insight·2025
Same author

Scaffolding Clinical Experiences to Support Student Learning, Skill Acquisition, and Increase Exposure to Patient Care Experiences.

Nursing education perspectives·2025
Same author

The role of glycemic control and symptoms and symptom clusters in breast cancer survivors with type 2 diabetes.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2025
Same author

Equity Using Interventions for Pain and Depression (EQUIPD): A pilot randomized trial.

The journal of pain·2025

Related Experiment Video

Updated: Aug 20, 2025

Use of the Operant Orofacial Pain Assessment Device OPAD to Measure Changes in Nociceptive Behavior
12:20

Use of the Operant Orofacial Pain Assessment Device OPAD to Measure Changes in Nociceptive Behavior

Published on: June 10, 2013

21.3K

O-Know Opioid Knowledge Test: Development and Psychometric Testing in a Community Setting.

Virgil L Gregory1, Susan Ofner2, Rebecca J Ellis3

  • 1Indiana University School of Social Work, MSW Direct Indianapolis and United States United States.

Journal of Psychoactive Drugs
|November 21, 2022
PubMed
Summary

This study developed the Opioid-Knowledge (O-Know) test to measure understanding of opioid use disorder (OUD) as a disease and its treatment. The O-Know test showed promise in assessing knowledge, potentially reducing stigma associated with OUD.

Keywords:
O-Know testeducationknowledgeopioid use disorderpsychometricstigma

More Related Videos

Functional Near-Infrared Spectroscopy Hyperscanning Study in Psychological Counseling
06:04

Functional Near-Infrared Spectroscopy Hyperscanning Study in Psychological Counseling

Published on: January 17, 2025

683
Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

18.6K

Related Experiment Videos

Last Updated: Aug 20, 2025

Use of the Operant Orofacial Pain Assessment Device OPAD to Measure Changes in Nociceptive Behavior
12:20

Use of the Operant Orofacial Pain Assessment Device OPAD to Measure Changes in Nociceptive Behavior

Published on: June 10, 2013

21.3K
Functional Near-Infrared Spectroscopy Hyperscanning Study in Psychological Counseling
06:04

Functional Near-Infrared Spectroscopy Hyperscanning Study in Psychological Counseling

Published on: January 17, 2025

683
Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

18.6K

Area of Science:

  • Psychology
  • Public Health
  • Medical Education

Background:

  • Stigma surrounding opioid use disorder (OUD) is a significant barrier to care and recovery.
  • Educational deficits contribute to the perpetuation of OUD stigma.
  • Developing reliable measures to assess knowledge about OUD is crucial for understanding and mitigating stigma.

Purpose of the Study:

  • To develop and psychometrically evaluate the Opioid-Knowledge (O-Know) test.
  • To assess the knowledge of OUD as a disease and its treatment in a community setting.
  • To provide a tool for measuring educational deficits related to OUD.

Main Methods:

  • A social media strategy recruited 294 participants from a midwestern region.
  • Factor analysis (tetrachoric correlation, principal axis factoring, Promax rotation) was used to evaluate the O-Know test structure.
  • Reliability (Cronbach's alpha) and convergent validity (correlation with personal stigmatization) were assessed.

Main Results:

  • Factor analysis supported a two-factor model: OUD as a Disease (Cronbach's alpha = .57) and OUD Treatment and Recovery (Cronbach's alpha = .62).
  • Reliability estimates were adequate for group-level use.
  • The OUD Treatment and Recovery factor negatively correlated with personal opioid stigmatization (B = -.29, p = .001), indicating partial convergent validity.

Conclusions:

  • The O-Know scale demonstrates psychometric properties suitable for assessing knowledge about OUD.
  • The O-Know test can help identify educational deficits and measure the impact of interventions aimed at reducing OUD stigma.
  • Further research using validated measures like O-Know is essential for advancing OUD research and practice.